Arrowhead制药 ARWR 深 沪
等待开盘 03-27 09:30:00 美东时间
60.80
+0.030
+0.05%
华盛通- 最 高67.15
- 今 开56.71
- 成交量 206.33万股
- 最 低 54.02
- 昨 收 60.77
- 总市值 644.48万
- 52周最高 76.76
- 市盈率 静 --
- 换手率 1946.53%
- 52周最低 9.57
- 委 比 24.05%
- 总股本 0.00亿
- 历史最高 93.66
- 量 比 1.25
- 振 幅 21.61%
- 历史最低 1.10
- 每 手 1
- 风险率 21.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is CRISPR Therapeutics Stock Surging Thursday?
CRSP shares jump on earnings report, strong pipeline for gene therapy. Revenue grows with increased patient treatment and analyst confidence.
02-27 02:45
Earnings Scheduled For February 5, 2026
Companies Reporting Before The Bell • WEC Energy Group (NYSE:WEC) is estimated ...
02-05 19:11
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials
Arrowhead Pharmaceuticals reported early trial data showing notable reductions in body, liver, and visceral fat from two experimental obesity drugs, with more results expected in 2026.
01-06 23:32
Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
2025-12-01 20:29
Gold Gains Over 1%; Nutanix Shares Fall After Q1 Results
U.S. stocks traded higher midway through trading, with the Dow Jones index gain...
2025-11-27 01:16
Arrowhead Pharmaceuticals Earns $200M Milestone Payment From Sarepta Therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has earned a $200 million milestone payment from Sarepta Therapeutics (NASDAQ:SRPT). The milestone was earned when Arrowhead achieved the second
2025-11-24 20:31
FDA Clears Arrowhead Pharma's First-Ever Home Injection For Rare Fat Disorder
Arrowhead Pharmaceuticals won FDA approval for Redemplo (plozasiran), an siRNA drug reducing high triglycerides in adults with rare FCS.
2025-11-19 02:07
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.
2025-03-11 02:02
Arrowhead Pharmaceuticals Files for Phase 1/2a Trial of New Obesity Treatment, ARO-INHBE
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi)
2024-09-23 19:31
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.
2024-09-05 19:04
